Open AccessImmunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer
Author(s) -
Sounak Gupta,
Chad Vanderbilt,
Wassim Abida,
Samson W. Fine,
Satish K. Tickoo,
Hikmat AlAhmadie,
Ying-Bei Chen,
S. Joseph Sirintrapun,
Kalyani Chadalavada,
Gouri J. Nanjangud,
Ann Bialik,
Michael J. Morris,
Howard I. Scher,
Marc Ladanyi,
Victor E. Reuter,
Anuradha Gopalan
Publication year - 2020
Publication title -
prostate cancer and prostatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2
H-Index - 64
eISSN - 1476-5608
pISSN - 1365-7852
DOI - 10.1038/s41391-020-0214-6
Subject(s) - prostate cancer , androgen receptor , immunohistochemistry , medicine , pathology , enzalutamide , neuroendocrine differentiation , prostate , adenocarcinoma , cancer , cancer research
Molecular and immunohistochemistry-based profiling of prostatic adenocarcinoma has revealed frequent Androgen Receptor (AR) gene and protein alterations in metastatic disease. This includes an AR-null non-neuroendocrine phenotype of metastatic castrate resistant prostate cancer which may be less sensitive to androgen receptor signaling inhibitors. This AR-null non-neuroendocrine phenotype is thought to be associated with TP53 and RB1 alterations. Herein, we have correlated molecular profiling of metastatic castrate resistant prostate cancer with AR/P53/RB immunohistochemistry and relevant clinical correlates.